— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results
Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored the application of biomarker testing in the U.S., as well as the turnaround time of the test results and the time it takes to go from diagnosis to first-line therapy. But how should you manage the patient while they wait?
In this third of four exclusive episodes, MedPage Today brought together three leaders in the field — moderator Vinay Prasad, MD, of the University of California San Francisco, is joined by Chul Kim, MD, of Georgetown University and MedStar Health in Washington, D.C., and Andrae Vandross, MD, of NEXT Oncology in San Antonio and Austin — for a roundtable discussion on this issue.
See full article